Positron Emission Tomography - Market Insights, Competitive Landscape, and Market Forecast - 2032
Description
Positron Emission Tomography Summary
The global positron emission tomography is expected to increase from USD 1,933.85 million in 2024 to USD 3,127.40 million by 2032, reflecting strong and sustained growth.
The global positron emission tomography is growing at a CAGR of 6.23% during the forecast period from 2025 to 2032.
The market of positron emission tomography solutions is being primarily driven by the rising prevalence of chronic diseases such as cardiovascular and neurological disorders, including Alzheimer's disease, and increasing technological advancements globally.
The leading companies operating in the positron emission tomography include General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.
North America is anticipated to dominate the overall positron emission tomography market. The region's market growth is primarily driven by increasing instances of chronic diseases such as cancer and neurodegenerative conditions like Parkinson's disease.
In the type segment of the positron emission tomography, the Full-Ring PET ccanners category is estimated to account for the largest market share in 2024.
Factors Contributing to the Growth of Positron Emission Tomography
Rising Prevalence of Chronic Diseases: The growing cases of chronic diseases are a major factor fueling the adoption of PET imaging. Conditions such as cancer, cardiovascular disorders, and neurological diseases, including Alzheimer’s, require accurate and early diagnostic tools for effective management. PET provides high sensitivity in detecting functional abnormalities at the molecular level, making it indispensable in disease staging, monitoring, and treatment planning. For instance, as the global population ages, the prevalence of neurodegenerative and oncological conditions continues to rise, creating a substantial patient pool that relies on PET imaging for timely diagnosis and care.
Technological Advancements in Positron Emission Tomography Modalities Fueling Market Growth: Continuous advancements and innovations in PET imaging technologies are significantly improving diagnostic precision and expanding the scope of applications. Developments such as hybrid PET/CT and PET/MRI systems, total-body PET scanners with higher sensitivity, and novel radiotracers are enabling earlier detection of diseases and more comprehensive evaluation of treatment responses. For example, total-body PET technology reduces scan times and radiation exposure while providing superior image quality, making it particularly valuable for oncology, cardiology, and neurology. These advancements are strengthening the clinical utility of PET and accelerating its global adoption.
Integration with Other Imaging Modalities: The integration of PET with complementary imaging techniques such as CT and MRI has significantly enhanced diagnostic capabilities by combining functional and anatomical insights in a single scan. While PET captures metabolic and molecular activity, CT and MRI provide detailed structural visualization, resulting in more accurate disease detection, staging, and treatment planning. This multimodal approach improves diagnostic confidence, supports precision medicine, and is increasingly becoming the standard in advanced clinical imaging. As healthcare systems continue to emphasize cost-effectiveness and better patient outcomes, the adoption of integrated PET-based imaging solutions is expected to rise steadily.
Positron Emission Tomography Report Segmentation
This positron emission tomography report offers a comprehensive overview of the global positron emission tomography, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Positron Emission Tomography by Type (Full-Ring PET Scanners, Partial Ring PET Scanners), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospital, Diagnostic Imaging Centres, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing positron emission tomography market.
Positron emission tomography (PET) is a non-invasive nuclear imaging technique that provides detailed insights into the body’s metabolic and physiological processes. By using radiotracers that emit positrons, PET captures high-resolution images to detect abnormal cellular activity, enabling early diagnosis and monitoring of conditions such as cancer, cardiovascular disease, and neurological disorders. Its ability to reveal functional changes at the molecular level, often before structural abnormalities appear, makes PET a critical tool in precision diagnostics, treatment planning, and personalized medicine.
The growth of the global PET market is primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which is creating a strong demand for accurate and early diagnostic solutions. Alongside this, continuous technological advancements, including hybrid imaging systems, novel radiotracers, and total-body PET scanners, are significantly enhancing diagnostic precision and broadening clinical applications. Furthermore, the integration of PET with other imaging modalities such as CT and MRI is improving diagnostic confidence, treatment planning, and overall patient management. Collectively, these factors are positioning PET as a vital tool in modern healthcare, supporting its robust market growth during the forecast period from 2025 to 2032.
Get More Insights into the Report @Positron Emission Tomography
What are the latest Positron Emission Tomography Dynamics and Trends?
The increasing global cases of chronic disorders, particularly cancer, cardiovascular diseases, and neurological conditions, are a primary factor for the growth of the PET market. PET imaging has become an indispensable tool in oncology, cardiology, and neurology by enabling highly sensitive detection of metabolic and functional changes at the molecular level, often before structural abnormalities appear. This early diagnostic advantage allows for accurate disease staging, monitoring of treatment response, and more personalized therapeutic strategies, making PET central to the management of some of the world’s most prevalent and life-threatening conditions. According to DelveInsight’s recent estimates, the number of new cancer cases globally is projected to rise significantly, surpassing 30 million by 2050, primarily due to population growth and aging. This mounting burden is creating a sustained demand for advanced imaging solutions capable of delivering precise, real-time insights into disease progression.
The rising cases of cardiovascular and neurological disorders further underscore the critical role of PET in modern healthcare. In cardiology, PET is increasingly applied to assess myocardial perfusion and viability, helping guide interventions for millions affected by heart disease. In neurology, PET is instrumental in diagnosing and tracking neurodegenerative conditions such as Alzheimer’s disease, offering clinicians vital information for patient management as these disorders continue to escalate worldwide. The market is not only responding to this demand but is also being reshaped by technological innovation. A recent example includes Brightonix Imaging’s announcement that its flagship product, the PHAROS PET Scanner, received FDA clearance for commercial distribution in the United States. This milestone marks a new era of precision and efficiency in nuclear imaging, positioning Brightonix Imaging at the forefront of medical innovation and setting new standards in diagnostic accuracy.
While Positron Emission Tomography offers unmatched functional and molecular insights, its growth is restrained by the presence of alternative imaging options and stringent regulatory frameworks. Conventional modalities such as CT and MRI are more widely available, less costly, and free from radiation exposure, making them preferred choices in many diagnostic scenarios and limiting PET adoption to complex cases requiring deeper metabolic analysis. Adding to this challenge are the rigorous approval processes for PET scanners and radiopharmaceuticals, which involve extensive safety testing, high compliance costs, and prolonged timelines. These constraints collectively slow down innovation, increase market entry barriers, and restrict wider accessibility of PET technologies despite their proven clinical value.
Positron Emission Tomography Segment Analysis
Positron Emission Tomography by Type (Full-Ring PET Scanners and Partial Ring PET Scanners), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospital, Diagnostic Imaging Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
By Type: Full-Ring PET Scanners Category Dominates the Market
Within the type segment of positron emission tomography, Full-Ring PET Scanners are a dominant force, projected to maintain a significant market share of around 65% in 2024. The market for full-ring PET scanners is expanding at an accelerated pace, driven by their unparalleled ability to deliver high-resolution, whole-body imaging with superior sensitivity. These systems utilize a complete 360-degree detector ring, enabling simultaneous acquisition of comprehensive data and reducing image artifacts, which results in sharper images and more reliable diagnostic outcomes. This makes them particularly valuable in oncology for detecting tumors at earlier stages, in cardiology for assessing myocardial perfusion with precision, and in neurology for mapping complex brain disorders such as Alzheimer’s disease.
Technological progress has further reinforced this trend, with the integration of silicon photomultipliers (SiPMs) and advanced time-of-flight (TOF) capabilities significantly improving image clarity while cutting down on scan times and radiation doses. Product development is also playing a vital role in shaping adoption: GE Healthcare’s Discovery MI Gen 2 has set new benchmarks for clinical accuracy, Siemens Healthineers’ Biograph Vision Quadra offers an extended axial field of view for faster and more detailed imaging, and United Imaging’s groundbreaking uEXPLORER provides total-body PET imaging, enabling dynamic studies that were previously unattainable. Collectively, these innovations are expanding the clinical utility of full-ring PET scanners beyond conventional oncology into areas like immunotherapy monitoring, pharmacokinetic studies, and population health research, thereby propelling their rapid market growth worldwide.
By Application: Oncology Category Dominates the Market
In the application segment, oncology continues to dominate the positron emission tomography (PET) market, accounting for more than 55% of the market share in 2024, serving as its primary growth factor. The rising global burden of cancers such as lung, liver, kidney, and bone has intensified the demand for precise imaging solutions that enable early detection, accurate staging, and effective treatment monitoring. PET imaging, with its ability to visualize metabolic activity at the cellular level, has become an indispensable tool in oncology, offering clinicians vital insights into tumor behavior and treatment response. Furthermore, the integration of PET with advanced modalities like PET/CT and PET/MRI is enhancing diagnostic accuracy and expanding its clinical utility across a wider range of malignancies. Collectively, these factors firmly position oncology as the leading driver of PET adoption worldwide..
By End-User: Hospitals Category Dominates the Market
The hospital segment dominates the end-user landscape of the positron emission tomography (PET) market, accounting for approximately 60% of the market share in 2024, largely due to its role as a primary hub for advanced diagnostic imaging. Hospitals are equipped with the infrastructure and resources necessary to house full-scale PET systems, which require specialized facilities, radioactive tracer handling, and integration with complementary imaging modalities like CT or MRI. They also benefit from access to multidisciplinary teams of oncologists, neurologists, cardiologists, and radiologists, who rely on PET scans for accurate diagnosis, staging, and treatment monitoring of complex conditions. Moreover, favorable reimbursement policies, high patient inflow, and the rising demand for early cancer and neurological disorder detection further reinforce hospitals as the preferred setting for PET imaging. While diagnostic imaging centers are expanding their presence with cost-effective offerings, hospitals are expected to maintain the largest market share, driven by their comprehensive service capabilities and ability to manage high-acuity cases.
Positron Emission Tomography Regional Analysis
North America Positron Emission Tomography Trends
In 2024, North America is projected to account for the largest share of the global positron emission tomography market, representing approximately 40%, driven by the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders like Parkinson’s disease. The region’s growth is further supported by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of leading imaging technology providers. The U.S. remains the frontrunner, with rapid adoption of innovative PET systems and substantial investments in R&D reinforcing its leadership position.
The United States, in particular, faces a significant and growing number of cancer cases. According to DelveInsight analysis, more than 1.85 million new cancer cases are expected to be diagnosed in the U.S. in 2025, and this number is projected to increase in the coming years due to an aging population and other demographic shifts. Thus, the growing burden of cancer in the United States is significantly fueling the adoption of PET imaging, as it enables accurate diagnosis, staging, and treatment monitoring. With the aging population and shifting demographics further increasing disease prevalence, the demand for advanced PET systems continues to rise.
Beyond oncology, the PET market is also being propelled by the rising cases of neurological disorders. Analysts highlight that nearly one million people in the U.S. are currently living with Parkinson’s disease, a figure expected to rise to 1.21 million by 2030. This growing disease burden, combined with North America’s advanced healthcare infrastructure, high healthcare expenditure, and strong preference for minimally invasive diagnostic procedures, continues to drive market growth in the region.
Europe Positron Emission Tomography Trends
The Europe positron emission tomography market is witnessing steady growth, supported by the rising incidence of cancer and neurological disorders, coupled with an increasing focus on early and accurate diagnosis. Strong government initiatives to improve cancer screening programs, favorable reimbursement frameworks, and the widespread adoption of advanced imaging technologies are further accelerating adoption. The presence of leading research institutions and collaborations between healthcare providers and imaging companies are fostering innovation, particularly in hybrid PET modalities and radiotracer development. Additionally, growing investments in precision medicine and personalized treatment approaches are enhancing the clinical value of PET, positioning Europe as a vital hub for technological advancement and market expansion.
Asia-Pacific Positron Emission Tomography Trends
The Asia-Pacific positron emission tomography (PET) market is witnessing rapid growth, driven by the rising incidence of cancer, cardiovascular disorders, and neurological conditions across the region. Increasing healthcare expenditure, expanding access to advanced diagnostic imaging, and government initiatives to strengthen cancer screening and early detection programs are further fueling adoption. Countries such as China, Japan, and India are emerging as key markets, supported by a growing patient pool, rising awareness of early disease diagnosis, and the availability of more cost-effective PET technologies. Moreover, collaborations between global manufacturers and local healthcare providers are enhancing access to cutting-edge imaging systems. With continuous investments in healthcare infrastructure and an expanding medical tourism industry, the Asia-Pacific is expected to be one of the fastest-growing regions in the global PET market.
Who are the major players in Positron Emission Tomography?
The following are the leading companies in Positron Emission Tomography. These companies collectively hold the largest market share and dictate industry trends.
General Electric Company
Bruker Corporation
Siemens Healthcare GmbH
Koninklijke Philips N.V.
Canon Medical Systems Corporation
Positron Corporation
Shimadzu Corp.
RefleXion
CMR Naviscan Corporation
Segami Corporation
Neusoft Medical Systems Co., Ltd.
Mediso Ltd.
Sofie Biosciences (PerkinElmer Inc.)
United Imaging Healthcare Co., Ltd.
MinFound Medical Systems Co., Ltd
MR Solutions
How is the competitive landscape shaping the Positron emission tomography?
The competitive landscape of the PET market is moderately concentrated, with a few global leaders driving technological innovation and commanding significant market share, while regional players and emerging startups contribute to specialized advancements. Leading companies are investing heavily in R&D to introduce next-generation PET solutions that feature hybrid imaging modalities, improved radiotracers, and AI-powered analysis, pushing the industry toward faster, safer, and more precise diagnostics. Key competitive strategies include continuous product innovation, strategic collaborations with hospitals, research institutions, and pharmaceutical firms, as well as expansion into new clinical applications such as neurology and cardiology. Meanwhile, regional players are gaining traction in emerging markets by offering cost-effective systems and localized radiotracer production. Overall, competition in the PET market is intensifying as both established players and new entrants strive to capture opportunities driven by rising disease prevalence, growing demand for precision diagnostics, and rapid technological progress.
Recent Developmental Activities in Positron Emission Tomography
In June 2025, GE HealthCare announced that the U.S. Food and Drug Administration approved an updated label for its PET imaging agent Vizamyl™ (flutemetamol F 18 injection) for beta-amyloid detection.
In Feb 2025, Telix Pharmaceuticals announced that the FDA accepted the Biologics License Application (BLA) for TLX250-CDx (Zircaix®), a breakthrough kidney cancer PET imaging agent. The FDA granted a Priority Review and set a PDUFA date of August 27, 2025, for a potential U.S. launch.
Positron Emission Tomography Segmentation
Positron Emission Tomography Type Exposure
Canada
Mexico
Germany
France
Italy
Spain
Rest of Europe
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East
Africa
Impact Analysis
AI-Powered Innovations and Applications:
Artificial Intelligence (AI) is transforming the PET market by bringing greater precision, efficiency, and clinical value to imaging. AI-driven algorithms enhance image reconstruction, reduce noise, and minimize radiation exposure, resulting in clearer images and safer procedures for patients. These technologies also enable automated quantification and pattern recognition, allowing for earlier and more reliable detection of conditions such as cancer, Alzheimer’s disease, and cardiovascular disorders. Beyond diagnostics, AI supports workflow optimization, predictive scheduling, and personalized treatment planning, helping healthcare providers improve efficiency and patient outcomes. Its growing role in clinical trials and drug development further expands the utility of PET imaging, positioning AI-powered PET as a critical enabler of precision medicine and next-generation healthcare delivery.
U.S. Tariff Impact Analysis on Positron Emission Tomography:
Tariffs play a critical role in shaping the cost dynamics of advanced medical imaging technologies such as PET systems. The U.S. healthcare market is highly dependent on imported PET scanners, radiotracers, and key components sourced from global manufacturers. Any increase in import tariffs on medical imaging equipment or electronic components directly raises procurement costs for healthcare providers, thereby impacting overall market growth. Higher tariffs can also affect the supply chain by creating price fluctuations, delaying the adoption of advanced systems, and increasing the financial burden on hospitals and diagnostic centers.
At the same time, tariffs may encourage domestic manufacturing and investment in U.S.-based production facilities for PET systems and radiopharmaceuticals, potentially reducing long-term reliance on imports. However, given the highly specialized nature of PET technology, short-term disruptions are more likely to hinder adoption than stimulate immediate local production. For market players, this underscores the importance of strategic planning, including diversifying supply chains, negotiating tariff adjustments, and exploring local assembly options to mitigate risks.
How This Analysis Helps Clients
Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.
Key takeaways from the Positron Emission Tomography report study
1. What is the growth rate of the positron emission tomography market?
The positron emission tomography is estimated to grow at a CAGR of 6.23% during the forecast period from 2025 to 2032.
2. What is the market for positron emission tomography?
The positron emission tomography was valued at USD 1,933.85 million in 2024, and is expected to reach USD 3,127.40 million by 2032.
3. Which region has the highest share in positron emission tomography?
North America is projected to hold the largest share of the global positron emission tomography market in 2024, driven by the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders like Parkinson’s disease. The region’s growth is further supported by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of leading imaging technology providers. The U.S. remains the frontrunner, with rapid adoption of innovative PET systems and substantial investments in R&D reinforcing its leadership position.
4. What are the drivers for positron emission tomography?
The growth of the global PET market is primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which is creating a strong demand for accurate and early diagnostic solutions. Alongside this, continuous technological advancements, including hybrid imaging systems, novel radiotracers, and total-body PET scanners, are significantly enhancing diagnostic precision and broadening clinical applications. Furthermore, the integration of PET with other imaging modalities such as CT and MRI is improving diagnostic confidence, treatment planning, and overall patient management. Collectively, these factors are positioning PET as a vital tool in modern healthcare, supporting its robust market growth during the forecast period from 2025 to 2032.
5. Who are the key players operating in positron emission tomography?
Some of the key market players operating in the positron emission tomography include General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.
The global positron emission tomography is expected to increase from USD 1,933.85 million in 2024 to USD 3,127.40 million by 2032, reflecting strong and sustained growth.
The global positron emission tomography is growing at a CAGR of 6.23% during the forecast period from 2025 to 2032.
The market of positron emission tomography solutions is being primarily driven by the rising prevalence of chronic diseases such as cardiovascular and neurological disorders, including Alzheimer's disease, and increasing technological advancements globally.
The leading companies operating in the positron emission tomography include General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.
North America is anticipated to dominate the overall positron emission tomography market. The region's market growth is primarily driven by increasing instances of chronic diseases such as cancer and neurodegenerative conditions like Parkinson's disease.
In the type segment of the positron emission tomography, the Full-Ring PET ccanners category is estimated to account for the largest market share in 2024.
Factors Contributing to the Growth of Positron Emission Tomography
Rising Prevalence of Chronic Diseases: The growing cases of chronic diseases are a major factor fueling the adoption of PET imaging. Conditions such as cancer, cardiovascular disorders, and neurological diseases, including Alzheimer’s, require accurate and early diagnostic tools for effective management. PET provides high sensitivity in detecting functional abnormalities at the molecular level, making it indispensable in disease staging, monitoring, and treatment planning. For instance, as the global population ages, the prevalence of neurodegenerative and oncological conditions continues to rise, creating a substantial patient pool that relies on PET imaging for timely diagnosis and care.
Technological Advancements in Positron Emission Tomography Modalities Fueling Market Growth: Continuous advancements and innovations in PET imaging technologies are significantly improving diagnostic precision and expanding the scope of applications. Developments such as hybrid PET/CT and PET/MRI systems, total-body PET scanners with higher sensitivity, and novel radiotracers are enabling earlier detection of diseases and more comprehensive evaluation of treatment responses. For example, total-body PET technology reduces scan times and radiation exposure while providing superior image quality, making it particularly valuable for oncology, cardiology, and neurology. These advancements are strengthening the clinical utility of PET and accelerating its global adoption.
Integration with Other Imaging Modalities: The integration of PET with complementary imaging techniques such as CT and MRI has significantly enhanced diagnostic capabilities by combining functional and anatomical insights in a single scan. While PET captures metabolic and molecular activity, CT and MRI provide detailed structural visualization, resulting in more accurate disease detection, staging, and treatment planning. This multimodal approach improves diagnostic confidence, supports precision medicine, and is increasingly becoming the standard in advanced clinical imaging. As healthcare systems continue to emphasize cost-effectiveness and better patient outcomes, the adoption of integrated PET-based imaging solutions is expected to rise steadily.
Positron Emission Tomography Report Segmentation
This positron emission tomography report offers a comprehensive overview of the global positron emission tomography, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Positron Emission Tomography by Type (Full-Ring PET Scanners, Partial Ring PET Scanners), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospital, Diagnostic Imaging Centres, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing positron emission tomography market.
Positron emission tomography (PET) is a non-invasive nuclear imaging technique that provides detailed insights into the body’s metabolic and physiological processes. By using radiotracers that emit positrons, PET captures high-resolution images to detect abnormal cellular activity, enabling early diagnosis and monitoring of conditions such as cancer, cardiovascular disease, and neurological disorders. Its ability to reveal functional changes at the molecular level, often before structural abnormalities appear, makes PET a critical tool in precision diagnostics, treatment planning, and personalized medicine.
The growth of the global PET market is primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which is creating a strong demand for accurate and early diagnostic solutions. Alongside this, continuous technological advancements, including hybrid imaging systems, novel radiotracers, and total-body PET scanners, are significantly enhancing diagnostic precision and broadening clinical applications. Furthermore, the integration of PET with other imaging modalities such as CT and MRI is improving diagnostic confidence, treatment planning, and overall patient management. Collectively, these factors are positioning PET as a vital tool in modern healthcare, supporting its robust market growth during the forecast period from 2025 to 2032.
Get More Insights into the Report @Positron Emission Tomography
What are the latest Positron Emission Tomography Dynamics and Trends?
The increasing global cases of chronic disorders, particularly cancer, cardiovascular diseases, and neurological conditions, are a primary factor for the growth of the PET market. PET imaging has become an indispensable tool in oncology, cardiology, and neurology by enabling highly sensitive detection of metabolic and functional changes at the molecular level, often before structural abnormalities appear. This early diagnostic advantage allows for accurate disease staging, monitoring of treatment response, and more personalized therapeutic strategies, making PET central to the management of some of the world’s most prevalent and life-threatening conditions. According to DelveInsight’s recent estimates, the number of new cancer cases globally is projected to rise significantly, surpassing 30 million by 2050, primarily due to population growth and aging. This mounting burden is creating a sustained demand for advanced imaging solutions capable of delivering precise, real-time insights into disease progression.
The rising cases of cardiovascular and neurological disorders further underscore the critical role of PET in modern healthcare. In cardiology, PET is increasingly applied to assess myocardial perfusion and viability, helping guide interventions for millions affected by heart disease. In neurology, PET is instrumental in diagnosing and tracking neurodegenerative conditions such as Alzheimer’s disease, offering clinicians vital information for patient management as these disorders continue to escalate worldwide. The market is not only responding to this demand but is also being reshaped by technological innovation. A recent example includes Brightonix Imaging’s announcement that its flagship product, the PHAROS PET Scanner, received FDA clearance for commercial distribution in the United States. This milestone marks a new era of precision and efficiency in nuclear imaging, positioning Brightonix Imaging at the forefront of medical innovation and setting new standards in diagnostic accuracy.
While Positron Emission Tomography offers unmatched functional and molecular insights, its growth is restrained by the presence of alternative imaging options and stringent regulatory frameworks. Conventional modalities such as CT and MRI are more widely available, less costly, and free from radiation exposure, making them preferred choices in many diagnostic scenarios and limiting PET adoption to complex cases requiring deeper metabolic analysis. Adding to this challenge are the rigorous approval processes for PET scanners and radiopharmaceuticals, which involve extensive safety testing, high compliance costs, and prolonged timelines. These constraints collectively slow down innovation, increase market entry barriers, and restrict wider accessibility of PET technologies despite their proven clinical value.
Positron Emission Tomography Segment Analysis
Positron Emission Tomography by Type (Full-Ring PET Scanners and Partial Ring PET Scanners), Application (Oncology, Cardiology, Neurology, and Others), End-User (Hospital, Diagnostic Imaging Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
By Type: Full-Ring PET Scanners Category Dominates the Market
Within the type segment of positron emission tomography, Full-Ring PET Scanners are a dominant force, projected to maintain a significant market share of around 65% in 2024. The market for full-ring PET scanners is expanding at an accelerated pace, driven by their unparalleled ability to deliver high-resolution, whole-body imaging with superior sensitivity. These systems utilize a complete 360-degree detector ring, enabling simultaneous acquisition of comprehensive data and reducing image artifacts, which results in sharper images and more reliable diagnostic outcomes. This makes them particularly valuable in oncology for detecting tumors at earlier stages, in cardiology for assessing myocardial perfusion with precision, and in neurology for mapping complex brain disorders such as Alzheimer’s disease.
Technological progress has further reinforced this trend, with the integration of silicon photomultipliers (SiPMs) and advanced time-of-flight (TOF) capabilities significantly improving image clarity while cutting down on scan times and radiation doses. Product development is also playing a vital role in shaping adoption: GE Healthcare’s Discovery MI Gen 2 has set new benchmarks for clinical accuracy, Siemens Healthineers’ Biograph Vision Quadra offers an extended axial field of view for faster and more detailed imaging, and United Imaging’s groundbreaking uEXPLORER provides total-body PET imaging, enabling dynamic studies that were previously unattainable. Collectively, these innovations are expanding the clinical utility of full-ring PET scanners beyond conventional oncology into areas like immunotherapy monitoring, pharmacokinetic studies, and population health research, thereby propelling their rapid market growth worldwide.
By Application: Oncology Category Dominates the Market
In the application segment, oncology continues to dominate the positron emission tomography (PET) market, accounting for more than 55% of the market share in 2024, serving as its primary growth factor. The rising global burden of cancers such as lung, liver, kidney, and bone has intensified the demand for precise imaging solutions that enable early detection, accurate staging, and effective treatment monitoring. PET imaging, with its ability to visualize metabolic activity at the cellular level, has become an indispensable tool in oncology, offering clinicians vital insights into tumor behavior and treatment response. Furthermore, the integration of PET with advanced modalities like PET/CT and PET/MRI is enhancing diagnostic accuracy and expanding its clinical utility across a wider range of malignancies. Collectively, these factors firmly position oncology as the leading driver of PET adoption worldwide..
By End-User: Hospitals Category Dominates the Market
The hospital segment dominates the end-user landscape of the positron emission tomography (PET) market, accounting for approximately 60% of the market share in 2024, largely due to its role as a primary hub for advanced diagnostic imaging. Hospitals are equipped with the infrastructure and resources necessary to house full-scale PET systems, which require specialized facilities, radioactive tracer handling, and integration with complementary imaging modalities like CT or MRI. They also benefit from access to multidisciplinary teams of oncologists, neurologists, cardiologists, and radiologists, who rely on PET scans for accurate diagnosis, staging, and treatment monitoring of complex conditions. Moreover, favorable reimbursement policies, high patient inflow, and the rising demand for early cancer and neurological disorder detection further reinforce hospitals as the preferred setting for PET imaging. While diagnostic imaging centers are expanding their presence with cost-effective offerings, hospitals are expected to maintain the largest market share, driven by their comprehensive service capabilities and ability to manage high-acuity cases.
Positron Emission Tomography Regional Analysis
North America Positron Emission Tomography Trends
In 2024, North America is projected to account for the largest share of the global positron emission tomography market, representing approximately 40%, driven by the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders like Parkinson’s disease. The region’s growth is further supported by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of leading imaging technology providers. The U.S. remains the frontrunner, with rapid adoption of innovative PET systems and substantial investments in R&D reinforcing its leadership position.
The United States, in particular, faces a significant and growing number of cancer cases. According to DelveInsight analysis, more than 1.85 million new cancer cases are expected to be diagnosed in the U.S. in 2025, and this number is projected to increase in the coming years due to an aging population and other demographic shifts. Thus, the growing burden of cancer in the United States is significantly fueling the adoption of PET imaging, as it enables accurate diagnosis, staging, and treatment monitoring. With the aging population and shifting demographics further increasing disease prevalence, the demand for advanced PET systems continues to rise.
Beyond oncology, the PET market is also being propelled by the rising cases of neurological disorders. Analysts highlight that nearly one million people in the U.S. are currently living with Parkinson’s disease, a figure expected to rise to 1.21 million by 2030. This growing disease burden, combined with North America’s advanced healthcare infrastructure, high healthcare expenditure, and strong preference for minimally invasive diagnostic procedures, continues to drive market growth in the region.
Europe Positron Emission Tomography Trends
The Europe positron emission tomography market is witnessing steady growth, supported by the rising incidence of cancer and neurological disorders, coupled with an increasing focus on early and accurate diagnosis. Strong government initiatives to improve cancer screening programs, favorable reimbursement frameworks, and the widespread adoption of advanced imaging technologies are further accelerating adoption. The presence of leading research institutions and collaborations between healthcare providers and imaging companies are fostering innovation, particularly in hybrid PET modalities and radiotracer development. Additionally, growing investments in precision medicine and personalized treatment approaches are enhancing the clinical value of PET, positioning Europe as a vital hub for technological advancement and market expansion.
Asia-Pacific Positron Emission Tomography Trends
The Asia-Pacific positron emission tomography (PET) market is witnessing rapid growth, driven by the rising incidence of cancer, cardiovascular disorders, and neurological conditions across the region. Increasing healthcare expenditure, expanding access to advanced diagnostic imaging, and government initiatives to strengthen cancer screening and early detection programs are further fueling adoption. Countries such as China, Japan, and India are emerging as key markets, supported by a growing patient pool, rising awareness of early disease diagnosis, and the availability of more cost-effective PET technologies. Moreover, collaborations between global manufacturers and local healthcare providers are enhancing access to cutting-edge imaging systems. With continuous investments in healthcare infrastructure and an expanding medical tourism industry, the Asia-Pacific is expected to be one of the fastest-growing regions in the global PET market.
Who are the major players in Positron Emission Tomography?
The following are the leading companies in Positron Emission Tomography. These companies collectively hold the largest market share and dictate industry trends.
General Electric Company
Bruker Corporation
Siemens Healthcare GmbH
Koninklijke Philips N.V.
Canon Medical Systems Corporation
Positron Corporation
Shimadzu Corp.
RefleXion
CMR Naviscan Corporation
Segami Corporation
Neusoft Medical Systems Co., Ltd.
Mediso Ltd.
Sofie Biosciences (PerkinElmer Inc.)
United Imaging Healthcare Co., Ltd.
MinFound Medical Systems Co., Ltd
MR Solutions
How is the competitive landscape shaping the Positron emission tomography?
The competitive landscape of the PET market is moderately concentrated, with a few global leaders driving technological innovation and commanding significant market share, while regional players and emerging startups contribute to specialized advancements. Leading companies are investing heavily in R&D to introduce next-generation PET solutions that feature hybrid imaging modalities, improved radiotracers, and AI-powered analysis, pushing the industry toward faster, safer, and more precise diagnostics. Key competitive strategies include continuous product innovation, strategic collaborations with hospitals, research institutions, and pharmaceutical firms, as well as expansion into new clinical applications such as neurology and cardiology. Meanwhile, regional players are gaining traction in emerging markets by offering cost-effective systems and localized radiotracer production. Overall, competition in the PET market is intensifying as both established players and new entrants strive to capture opportunities driven by rising disease prevalence, growing demand for precision diagnostics, and rapid technological progress.
Recent Developmental Activities in Positron Emission Tomography
In June 2025, GE HealthCare announced that the U.S. Food and Drug Administration approved an updated label for its PET imaging agent Vizamyl™ (flutemetamol F 18 injection) for beta-amyloid detection.
In Feb 2025, Telix Pharmaceuticals announced that the FDA accepted the Biologics License Application (BLA) for TLX250-CDx (Zircaix®), a breakthrough kidney cancer PET imaging agent. The FDA granted a Priority Review and set a PDUFA date of August 27, 2025, for a potential U.S. launch.
Positron Emission Tomography Segmentation
Positron Emission Tomography Type Exposure
- Full-Ring PET Scanners
- Partial Ring PET Scanners
- Oncology
- Cardiology
- Neurology
- Others
- Hospitals
- Diagnostic Imaging Centres
- Others
- North America
Canada
Mexico
- Europe
Germany
France
Italy
Spain
Rest of Europe
- Asia-Pacific
Japan
India
Australia
South Korea
Rest of Asia-Pacific
- Rest of the World
Middle East
Africa
Impact Analysis
AI-Powered Innovations and Applications:
Artificial Intelligence (AI) is transforming the PET market by bringing greater precision, efficiency, and clinical value to imaging. AI-driven algorithms enhance image reconstruction, reduce noise, and minimize radiation exposure, resulting in clearer images and safer procedures for patients. These technologies also enable automated quantification and pattern recognition, allowing for earlier and more reliable detection of conditions such as cancer, Alzheimer’s disease, and cardiovascular disorders. Beyond diagnostics, AI supports workflow optimization, predictive scheduling, and personalized treatment planning, helping healthcare providers improve efficiency and patient outcomes. Its growing role in clinical trials and drug development further expands the utility of PET imaging, positioning AI-powered PET as a critical enabler of precision medicine and next-generation healthcare delivery.
U.S. Tariff Impact Analysis on Positron Emission Tomography:
Tariffs play a critical role in shaping the cost dynamics of advanced medical imaging technologies such as PET systems. The U.S. healthcare market is highly dependent on imported PET scanners, radiotracers, and key components sourced from global manufacturers. Any increase in import tariffs on medical imaging equipment or electronic components directly raises procurement costs for healthcare providers, thereby impacting overall market growth. Higher tariffs can also affect the supply chain by creating price fluctuations, delaying the adoption of advanced systems, and increasing the financial burden on hospitals and diagnostic centers.
At the same time, tariffs may encourage domestic manufacturing and investment in U.S.-based production facilities for PET systems and radiopharmaceuticals, potentially reducing long-term reliance on imports. However, given the highly specialized nature of PET technology, short-term disruptions are more likely to hinder adoption than stimulate immediate local production. For market players, this underscores the importance of strategic planning, including diversifying supply chains, negotiating tariff adjustments, and exploring local assembly options to mitigate risks.
How This Analysis Helps Clients
Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.
Key takeaways from the Positron Emission Tomography report study
- Market size analysis for the current positron emission tomography size (2024), and market forecast for 8 years (2025 to 2032)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
- Key companies dominating the positron emission tomography.
- Various opportunities available for the other competitors in the positron emission tomography space.
- What are the top-performing segments in 2024How these segments will perform in 2032?
- Which are the top-performing regions and countries in the current positron emission tomography scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for the positron emission tomography growth in the future?
1. What is the growth rate of the positron emission tomography market?
The positron emission tomography is estimated to grow at a CAGR of 6.23% during the forecast period from 2025 to 2032.
2. What is the market for positron emission tomography?
The positron emission tomography was valued at USD 1,933.85 million in 2024, and is expected to reach USD 3,127.40 million by 2032.
3. Which region has the highest share in positron emission tomography?
North America is projected to hold the largest share of the global positron emission tomography market in 2024, driven by the rising prevalence of chronic diseases such as cancer and neurodegenerative disorders like Parkinson’s disease. The region’s growth is further supported by its advanced healthcare infrastructure, favorable reimbursement framework, and strong presence of leading imaging technology providers. The U.S. remains the frontrunner, with rapid adoption of innovative PET systems and substantial investments in R&D reinforcing its leadership position.
4. What are the drivers for positron emission tomography?
The growth of the global PET market is primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which is creating a strong demand for accurate and early diagnostic solutions. Alongside this, continuous technological advancements, including hybrid imaging systems, novel radiotracers, and total-body PET scanners, are significantly enhancing diagnostic precision and broadening clinical applications. Furthermore, the integration of PET with other imaging modalities such as CT and MRI is improving diagnostic confidence, treatment planning, and overall patient management. Collectively, these factors are positioning PET as a vital tool in modern healthcare, supporting its robust market growth during the forecast period from 2025 to 2032.
5. Who are the key players operating in positron emission tomography?
Some of the key market players operating in the positron emission tomography include General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.
Table of Contents
150 Pages
- 1. Positron Emission Tomography Market Report Introduction
- 1.1. Scope of the Study
- 1.2. Market Segmentation
- 1.3. Market Assumption
- 2. Positron Emission Tomography Market Executive Summary
- 2.1. Market at Glance
- 3. Positron Emission Tomography Market Key Factors Analysis
- 3.1. Positron Emission Tomography Market Drivers
- 3.1.1. Rising prevalence of chronic diseases
- 3.1.2. Technological Advancements in Positron Emission Tomography Modalities
- 3.1.3. Integration with other imaging modalities
- 3.2. Positron Emission Tomography Market Restraints and Challenges
- 3.2.1. Availability of alternative options
- 3.2.2. Stringent regulatory approval
- 3.3. Positron Emission Tomography Market Opportunity
- 3.3.1. Development of novel radiotracers can enhance the specificity and sensitivity of PET scans
- 4. Impact Analysis
- 4.1. AI-Powered Innovations and Applications
- 4.2. U.S. Tariff Impact Analysis
- 5. Regulatory Analysis
- 5.1. The United States
- 5.2. Europe
- 5.3. Japan
- 5.4. China
- 6. Positron Emission Tomography Market Porter’s Five Forces Analysis
- 6.1. Bargaining Power of Suppliers
- 6.2. Bargaining Power of Consumers
- 6.3. Threat of New Entrants
- 6.4. Threat of Substitutes
- 6.5. Competitive Rivalry
- 7. Positron Emission Tomography Market Assessment
- 7.1. By Type
- 7.1.1. Full-Ring PET Scanners
- 7.1.2. Partial Ring PET Scanners
- 7.2. By Application
- 7.2.1. Oncology
- 7.2.2. Cardiology
- 7.2.3. Cardiology
- 7.2.4. Others
- 7.3. By End-Users
- 7.3.1. Hospitals
- 7.3.2. Diagnostic Imaging Centres
- 7.3.3. Others
- 7.4. By Geography
- 7.4.1. North America
- 7.4.1.1. United States Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.1.2. Canada Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.1.3. Mexico Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.2. Europe
- 7.4.2.1. France Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.2.2. Germany Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.2.3. United Kingdom Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.2.4. Italy Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.2.5. Spain Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.2.6. Rest of Europe Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.3. Asia-Pacific
- 7.4.3.1. China Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.3.2. Japan Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.3.3. India Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.3.4. Australia Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.3.5. South Korea Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.3.6. Rest of Asia-Pacific Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.4. Rest of the World (RoW)
- 7.4.4.1. Middle East Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.4.2. Africa Positron Emission Tomography Market Size in USD million (2022-2032)
- 7.4.4.3. South America Positron Emission Tomography Market Size In USD Million (2022-2032)
- 8. Competitive Landscape
- 9. Startup Funding & Investment Trends
- 10. Positron Emission Tomography Market Company and Product Profiles
- 10.1. General Electric Company
- 1.1.1. Company Overview
- 1.1.2. Company Snapshot
- 1.1.3. Financial Overview
- 1.1.4. Product Listing
- 1.1.5. Entropy
- 10.2. Bruker Corporation
- 1.1.6. Company Overview
- 1.1.7. Company Snapshot
- 1.1.8. Financial Overview
- 1.1.9. Product Listing
- 1.1.10. Entropy
- 10.3. Siemens Healthcare GmbH.
- 1.1.11. Company Overview
- 1.1.12. Company Snapshot
- 1.1.13. Financial Overview
- 1.1.14. Product Listing
- 1.1.15. Entropy
- 10.4. Koninklijke Philips N.V.
- 1.1.16. Company Overview
- 1.1.17. Company Snapshot
- 1.1.18. Financial Overview
- 1.1.19. Product Listing
- 1.1.20. Entropy
- 10.5. Canon Medical Systems Corporation
- 1.1.21. Company Overview
- 1.1.22. Company Snapshot
- 1.1.23. Financial Overview
- 1.1.24. Product Listing
- 1.1.25. Entropy
- 10.6. Positron Corporation
- 1.1.26. Company Overview
- 1.1.27. Company Snapshot
- 1.1.28. Financial Overview
- 1.1.29. Product Listing
- 1.1.30. Entropy
- 10.7. Shimadzu Corp.
- 1.1.31. Company Overview
- 1.1.32. Company Snapshot
- 1.1.33. Financial Overview
- 1.1.34. Product Listing
- 1.1.35. Entropy
- 10.8. RefleXion
- 1.1.36. Company Overview
- 1.1.37. Company Snapshot
- 1.1.38. Financial Overview
- 1.1.39. Product Listing
- 1.1.40. Entropy
- 10.9. CMR Naviscan Corporation
- 1.1.41. Company Overview
- 1.1.42. Company Snapshot
- 1.1.43. Financial Overview
- 1.1.44. Product Listing
- 1.1.45. Entropy
- 10.10. Segami Corporation
- 1.1.46. Company Overview
- 1.1.47. Company Snapshot
- 1.1.48. Financial Overview
- 1.1.49. Product Listing
- 1.1.50. Entropy
- 10.11. Neusoft Medical Systems Co., Ltd.
- 1.1.51. Compan Overview
- 1.1.52. Company Snapshot
- 1.1.53. Financial Overview
- 1.1.54. Product Listing
- 1.1.55. Entropy
- 10.12. Mediso Ltd.
- 1.1.56. Company Overview
- 1.1.57. Company Snapshot
- 1.1.58. Financial Overview
- 1.1.59. Product Listing
- 1.1.60. Entropy
- 10.13. Sofie Biosciences (PerkinElmer Inc.)
- 1.1.61. Company Overview
- 1.1.62. Company Snapshot
- 1.1.63. Financial Overview
- 1.1.64. Product Listing
- 1.1.65. Entropy
- 10.14. United Imaging Healthcare Co., Ltd.
- 1.1.66. Company Overview
- 1.1.67. Company Snapshot
- 1.1.68. Financial Overview
- 1.1.69. Product Listing
- 1.1.70. Entropy
- 10.15. MinFound Medical Systems Co., Ltd.
- 1.1.71. Company Overview
- 1.1.72. Company Snapshot
- 1.1.73. Financial Overview
- 1.1.74. Product Listing
- 1.1.75. Entropy
- 10.16. MR Solutions
- 1.1.76. Company Overview
- 1.1.77. Company Snapshot
- 1.1.78. Financial Overview
- 1.1.79. Product Listing
- 1.1.80. Entropy
- 11. KOL Views
- 12. Project Approach
- 13. About DelveInsight
- 14. Disclaimer & Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.